Default company panoramic image
Logo

PluroGen Therapeutics, Inc.

On track to be the 1st topical antibiotic for Diabetic Ulcers approved by FDA, PluroGen specializes in simple solutions for burns and wounds

  • Stage $500K in TTM Revenue
  • Industry Biotechnology
  • Location Norristown, PA, USA
  • Currency USD
  • Founded December 2005
  • Employees 6
  • Website plurogen.com

Company Summary

PluroGel products offer simple solutions for complex wounds through exclusive properties that are effective in all stages of wound healing. PluroGel Products create and maintain the ideal wound environment for the patient to do the healing. We have 3 products: PluroGel SINGLE (PSSD) currently sold in Europe and successfully treating chronic wounds, PluroGel PLAIN, for non-infected wounds, and PluroGel DOUBLE (PN) in Phase IIa FDA trials.

Team

  • Default avatar
    Neal Koller
    President & CEO

    PluroGen’s President and CEO is Neal Koller, a seasoned industry leader who combines many years of comprehensive pharmaceutical and medical device experience to position PluroGen Therapeutics for growth and success.

Advisors

  • Default avatar
    Pepper Hamilton
    Lawyer
    Unconfirmed
    Default avatar
    EisnerAmper
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Jefferson Corner Group
    Unconfirmed
    Default avatar
    Virginia Active Angel Network
    Unconfirmed
    Default avatar
    NJ Angels
    Unconfirmed